Welcome to CSNpharm! For Research Use Only!
FGFR
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN18656 | Sulfatinib | 1308672-74-3 | Sulfatinib is an inhbitor of KDR and FGFR1 with IC50 values of 0.021 M and 0.053 M respectively. It also shows inhibition of hERG (IC50 6.8 M). |
| CSN15810 | SSR128129E | 848318-25-2 | SSR128129E is an allosteric modulator of FGFR by binding to the extracellular FGFR domain |
| CSN18466 | SSR128129E Free Acid | 848463-13-8 | SSR128129E free acid is a multi-FGFR blocker with allosteric properties and inhibits FGFR signaling by binding to the extracellular FGFR domain without affecting orthosteric FGF binding |
| CSN22605 | S49076 HCl | 1265966-31-1 | S49076 hydrochloride is a potent, ATP-competitive tyrosine kinase inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 <20 nM. |
| CSN26937 | Rogaratinib | 1443530-05-9 | Rogaratinib is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. |
| CSN20388 | PRN1371 | 1802929-43-6 | PRN1371 is an irreversible covalent FGFR inhibitor used for the treatment of solid tumor |
| CSN21067 | Ponatinib HCl | 1114544-31-8 | Ponatinib is a multi-targeted kinase inhibitor with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src respectively. |
| CSN26440 | Pemigatinib | 1513857-77-6 | Pemigatinib, also known as INCB054828, is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. FGFR inhibitor INCB054828 binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. |
| CSN12916 | PD173074 | 219580-11-7 | PD173074 is a potent FGFR1 inhibitor with IC50 of 25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM 1000-fold selective for FGFR1 than PDGFR and c-Src |
| CSN13927 | PD166866 | 192705-79-6 | PD 166866 is a selective FGFR tyrosine kinase inhibitor with an IC50 of 524 nM |
| CSN23024 | PD 161570 | 192705-80-9 | PD 161570 is a selective FGFR inhibitor with IC50 of 40 nM. |
| CSN19223 | NSC 12 | 102586-30-1 | NSC 12 is an orally available pan-FGF trap able to inhibit FGF2FGFR interaction and endowed with promising antitumor activity |
| CSN22060 | MRX-2843 | 1429882-07-4 | MRX-2843 is an orally available small-molecule inhibitor of both MERTK and FLT3. |
| CSN16111 | LY2874455 | 1254473-64-7 | LY2874455 is a pan-FGFR inhibitor with IC50 of 28 nM 26 nM 64 nM and 6 nM for FGFR1 FGFR2 FGFR3 and FGFR4 respectively and also inhibits VEGFR2 activity with IC50 of 7 nM |
| CSN18841 | H3B-6527 | 1702259-66-2 | H3B-6527 acts as a selective FGFR4 inhibitor IC50 12 nM over FGFR1-3 |
| CSN13938 | FIIN-3 | 1637735-84-2 | FIIN-3 is an irreversible inhibitor of FGFR1-4 with IC50s of 13 21 31 and 35 nM respectively |
| CSN13937 | FIIN-2 | 1633044-56-0 | FIIN-2 is an irreversible inhibitor of FGFR1-4 with IC50 values of 31 43 27 and 45 nM respectively |
| CSN22818 | FIIN 1 HCl | 1256152-35-8 | FIIN 1 HCl is a potent, irreversible FGFR inhibitor with Kds of 2.8, 5.4, 6.9 and 120 nM for FGFR1, FGFR3, FGFR2 and FGFR4 respectively. |
| CSN18853 | FGFR4-IN-1 | 1708971-72-5 | FGFR4-IN-1 is a potent inhibiotr of FGFR4 with IC50 of 07 nM |
| CSN20012 | FGFR4 Inhibitor C(-)-11 | 2020395-38-2 | FGFR4 inhibitor C--11 is a highly potent FGFR4 inhibitor with selectivity over FGFR1 with good stability and CYP inhibition |
| CSN19155 | FGFR-IN-1 | 1448169-71-8 | FGFR-IN-1 is a potent and highly selective FGFR inhibitor used for antitumor treatment |
| CSN19757 | FGF401 | 1708971-55-4 | FGF401 an inhibitor of human fibroblast growth factor receptor 4 FGFR4 IC50 11 nM has potential antineoplastic activity |
| CSN17720 | Erdafitinib | 1346242-81-6 | Erdafitinib inhibits FGFR1 pIC50 9 FGFR2 pIC50 85 FGFR3 pIC50 85 and FGFR4 pIC50 825 and it is a quinoxaline derivative compound |
| CSN20555 | Derazantinib | 1234356-69-4 | Derazantinib is a fibroblast growth factor receptor FGFR inhibitor that has antitumor activity |
| CSN21245 | ARQ-087 2HCl | 1821329-75-2 | Derazantinib ARQ-087 is an ATP competitive tyrosine kinase inhibitor exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 45 18 and 45 nM respectively |
| CSN17224 | CH5183284 | 1265229-25-1 | CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. |
| CSN13925 | BLU9931 | 1538604-68-0 | BLU9931 is an inhibitor of FGFR4 with IC50 of 3 nM and is less potent for FGFR1/2/3 (IC50 > 150 nM). |
| CSN18780 | BLU-554 | 1707289-21-1 | BLU-554 is a selective inhibitor of FGFR4 with the IC50 of 5 nM |
| CSN17679 | NVP-BGJ398 Phosphate | 1310746-10-1 | BGJ398 Phosphate is a selective and potent inhibitor of FGFRs with IC50 values of 1nM for FGFR11-3 and 60nM for FGFR4, as well as 4.9nM for FGFR3-K650E mutant. |
| CSN16144 | BGJ398 | 872511-34-7 | BGJ-398 is a selective, pan-specific FGFR inhibitor with IC50 of 0.9, 1.4, and 1 nM for FGFR1, FGFR2, and FGFR3, respectively and > 40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. |
| CSN12890 | AZD4547 | 1035270-39-3 | AZD4547 is a selective FGFR inhibitor targeting FGFR123 with IC50 of 02 nM25 nM18 nM with weaker activity against FGFR4 VEGFR2 KDR and little activity observed against IGFR CDK2 and p38 |
| CSN19705 | ASP5878 | 1453208-66-6 | ASP5878 is a selective FGFR inhibitor to treat FGFR3-dependent urothelial cancer with or without chemoresistance |
| CSN22608 | Alofanib | 1612888-66-0 | Alofanib is a selective and allosteric inhibitor of FGFR2 with potential antitumor activity |
| CSN18610 | ACTB-1003 | 939805-30-8 | ACTB-1003 is a potent inhibitor of FGFR1 with IC50 10 nM in FGFR-1 biochemical assay |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
